This is an unmasking randomized clinical trial. the main purpose of this study is to analyze whether posvitrectomy proactive use of conbercept can reduce the rate of postoperative complication in PDR patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
80
preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
Peking University Third Hospital
Beijing, Beijing Municipality, China
RECRUITINGrate of postvitrectomy complication
postvitrectomy DME, VH (recurrent or nonabsorbent), NVG
Time frame: 6 months
postvitrectomy BCVA
BCVA at 1,3,6 month after vitrectomy
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.